Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 12 October 2023

 
 
 
   

How can innovation help address workforce shortages?

 
Read the full report here.

With 5 new cancer patients diagnosed every minute in Europe, experts estimate that the region will see a shortage of 4.1 million healthcare workers by 2030. This will put significant pressure on oncology care, resulting in delayed diagnoses and poorer health outcomes for patients, more pressurised staff and the subsequent impact on mental health, as well as an increasing number of staff shortages and longer waiting lists. 

Read EFPIA's latest report on Innovation for Sustainable Cancer Care.

Read more


 
 
 
   

Rethinking Alzheimer's Disease | Watch the event recording

 
 
 
 
   

Events

 

33rd Alzheimer Europe Conference
16 October 2023 (Helsinki, Finland, & virtual)

New opportunities in dementia care, policy and research Read more

EFGCP Better Medicines for Children Conference 2023
17 October 2023 (Amsterdam)

Global Paediatric Drug Development: the value of multi-stakeholders’ collaboration Read more

World Local Production Forum
06 November 2023 (The Hague, the Netherlands)

Enhancing access to medicines and other health technologies Read more

High-Level Conference on the Value and Role of Incentives in Life Science
07 November 2023 (Brussels, Belgium)

Under the auspices of the Ministry of Health of the Czech Republic Read more

 
 
 
   

More than 600 essential medicines at risk with new EU chemical proposal

Evidence shows that more than 600 essential medicines are at risk, and manufacturing in Europe will ‘grind to a halt’ if wide-ranging chemical ban on Per- and Polyfluoroalkyl Substances (PFAS) substances is implemented.

While we support the need to restrict certain PFAS, we need to find the right approach to ensure the continued manufacturing and availability of medicines in Europe. A total ban would see medicines’ manufacturing in the EU grind to a halt in under three years. It would also jeopardise the production of all pharmaceutical substances in Europe and would be in conflict with the EU’s strategy of reducing Europe's dependency in the event of shortages or pandemics.

Discover more here.

 
 
 
 
   

What we are reading

 
What’s in a name? Why unmet medical needs are riling the pharma industry
On 12 October 2023 (Politico)

This article is the product of a POLITICO Working Group presented by Sanofi.

Read more

How is the EU boosting support for innovation in the health sector?
On 05 October 2023 (Euronews)

In this latest episode of Smart Health, we ask why Europe is lagging behind other countries when it comes to medical... Read more